N@N

Sucampo Pharmaceuticals Inc (NASDAQ:SCMP), Up By 6.15% ($0.28) After BUYINS.NET SqueezeTrigger Report Released on Monday, Novem

^{Published on 2012-11-20 07:41:35 - WOPRAI}
 

November 20, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Monday, November 19th 2012 at 07:16:00 PST stating that Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) was expected to be Up After it crossed above its SqueezeTrigger Price of 4.52 on Monday, November 19th 2012. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=scmp&id=329080

From August 2009 to October 2012, an aggregate amount of 9272079 shares of SCMP have been shorted for a total dollar value of $37088316. The SCMP SqueezeTrigger price of $4.52 is the volume weighted average price that all shorts are short in shares of SCMP. There is still approximately $1,709,775 of potential short covering in shares of SCMP.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) - Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones primarily in the Americas, Europe, and Asia. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of open-angle glaucoma and ocular hypertension. In addition, the company is developing Amitiza for the treatment of opioid-induced bowel dysfunction, which completed two Phase III clinical trials; Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers, which completed a Phase IIa clinical trial; SPI-017, a Phase I clinical trial product, for the treatment of Peripheral arterial disease; and SPI-3608 for the treatment of spinal stenosis, which is under preclinical trial. Additionally, it is conducting a preclinical trial of Rescula for dry age related macular degeneration; and preclinical trials of Cobiprostone for the treatment of chronic obstructive pulmonary disease and wound healing. Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland..

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net